Arthur J. McCullough
Cleveland Clinic Lerner College of Medicine
148 Papers
1.4K Citations
Arthur J. McCullough is an academic researcher from Cleveland Clinic Lerner College of Medicine. The author has contributed to research in topics: Medicine & Fatty liver. The author has an hindex of 48, co-authored 148 publications. Previous affiliations of Arthur J. McCullough include MetroHealth & University of Rhode Island.
Chat about Author
Papers
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
Christi A. Matteoni,Zobair M. Younossi,Terry Gramlich,Navdeep Boparai,Yao Chang Liu,Arthur J. McCullough +5 more
TL;DR: The outcome of cirrhosis and liver-related death is not uniform across the spectrum of nonalcoholic fatty liver, and poor outcomes are more frequent in patients in whom biopsies show ballooning degeneration and Mallory hyaline or fibrosis.
3.5K
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Arun J. Sanyal,Naga Chalasani,Kris V. Kowdley,Arthur J. McCullough,Anna Mae Diehl,Nathan M. Bass,Brent A. Neuschwander-Tetri,Joel E. Lavine,James Tonascia,Aynur Unalp,Mark L. Van Natta,Jeanne M. Clark,Elizabeth M. Brunt,David E. Kleiner,Jay H. Hoofnagle,Patricia R. Robuck +15 more
TL;DR: Vitamin E was superior to placebo for the treatment of nonalcoholic steatohepatitis in adults without diabetes, and significant benefits of pioglitazone were observed for some of the secondary outcomes.
Nonalcoholic fatty liver disease a feature of the metabolic syndrome
Giulio Marchesini,Mara Brizi,Giampaolo Bianchi,Sara Tomassetti,Elisabetta Bugianesi,Marco Lenzi,Arthur J. McCullough,S. Natale,Gabriele Forlani,Nazario Melchionda +9 more
TL;DR: It is concluded that NAFLD, in the presence of normoglycemia and normal or moderately increased body weight, is characterized by clinical and laboratory data similar to those found in diabetes and obesity.
Insulin resistance: A metabolic pathway to chronic liver disease†
TL;DR: The ability of insulin‐sensitizing, pharmacological agents to treat NAFLD by reducing IR in the liver (metformin) and in the periphery (thiazolidinediones) are discussed.
922